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Abstract 
Deletions of the short arm of chromosome 1 are 
observed in a broad range of hematological 
malignances including myeloid disorders, acute 
lymphoblastic leukemia (ALL), multiple myeloma 
(MM) and lymphomas. They generally occur as part 
of complex karyotypes and in advanced disease 
stages. Their association with complex karyotypes 
likely reflect an inherent chromosomal instability 
correlated with a poor prognosis. The occurrence of 
1p deletions as a sole anomaly is infrequent and their 
clinical significance is less well characterized. 
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Partial karyotypes showing deletions of the short arm of chromosome 1 (A). Fluorescence in situ hybridization 
with LSI 1p36 (red)/1q25 (green) probes (Vysis/Abott Molecular, US) showing deletion of terminal 1p36 
sequences from chromosome 1 (absence of the red signal). 
Clinics and pathology 
Disease 
Myeloid malignancies, acute lymphoblastic 
leukemia (ALL) and multiple myeloma (MM) 
Epidemiology 
Myeloid malignancies mainly (10 patients): 5 
patients with myelodysplastic syndromes (MDS) (3 
males, 2 females aged 64 to 71 years) (Parlier  et al., 
1994; Westbrook  et al., 2000; Lubbert et al., 2001; 
Mallo et al., 2008; Wang et al., 2010; ) and 5 acute 
myeloid leukemia (AML) cases (2 males and 3 
females aged 16 to 46 years) (Raimondi et al., 1999; 
Lemez et al., 2000;  Coupland et al., 2002; Casas et 
al., 2004; Gmidène et al., 2012). In addition, there 
was 1 ALL patient (Zuelzer et al., 1976), a 7-years 
old T-ALL patient (Kaneko et al., 1989), 1 infant 
patient with biphenotypic leukemia (Al-Seraihy et 
al., 2009) and 7 multiple myeloma cases (3 males 
and 4 females aged 41 to 72 years) (Ankathil et al., 
1995; Calasanz  et al., 1997; Pantau et al., 2005). 
Cytogenetics 
Cytogenetics morphological 
Various breakpoints; found in a form of interstitial 
or terminal deletion, the most commonly breakpoint 
described is p11p22 found in 4 out of 7 MM cases; 
found in a sideline in 1 AML (Raimondi et al., 1999) 
and in 1 MM case (Pantou et al., 2005). 




Deletions of the short arm of chromosome 1 
represent nonrandom structural aberrations in 
hematological malignancies, suggesting the 
existence of tumor suppressor genes encoded in this 
region. Loss of genetic information from the deleted 
region may contribute to disease pathogenesis via 
dosage reduction of genes leading to their aberrant 
expression. Most 1p deletions involve large regions 
containing a certain fraction of genes, therefore 
multiple tumor suppressive genes might cooperate in 
an additive or synergistic way leading to their 
simultaneous downregulation 
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